TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06592638: A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT06592638 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06592638 Rescue Dossier →